|
2025 Conference Publication CS18 Effect of duloxetine on neuropathic symptom burden and objective neurophysiological parameters in chemotherapy-induced peripheral neuropathy: a crossover randomised controlled trialVu, Jennifer, Battaglini, Eva, Li, Tiffany, Wyld, David, Henderson, Robert, Marx, Gavin, Krishnan, Arun, Goldstein, David and Park, Susanna B (2025). CS18 Effect of duloxetine on neuropathic symptom burden and objective neurophysiological parameters in chemotherapy-induced peripheral neuropathy: a crossover randomised controlled trial. BMJ Publishing Group Ltd. doi: 10.1136/bmjno-2025-anzan.26 |
|
2025 Conference Publication Risk factors for dose-limiting, chronic and severe chemotherapy-induced peripheral neuropathyLi, Tiffany, Timmins, Hannah C., Horvath, Lisa G., Harrison, Michelle, Grimison, Peter, Friedlander, Michael, Marx, Gavin, Boyle, Frances, Wyld, David, Henderson, Robert, King, Tracy, Baron-Hay, Sally, Kiernan, Matthew C., Barnes, Elizabeth H., Goldstein, David and Park, Susanna B. (2025). Risk factors for dose-limiting, chronic and severe chemotherapy-induced peripheral neuropathy. Australian and New Zealand Association of Neurologists Clinical Neurophysiology Workshop, Gold Coast, QLD, Australia, 6-9 October 2024. Shannon, Ireland: Elsevier. doi: 10.1016/j.clinph.2025.2110921 |
|
2025 Conference Publication Phase Ib/IIa dose escalation and expansion study of 212Pb-ADVC001 in metastatic castration-resistant prostate cancer (mCRPC): TheraPb-Phase I/II Trial in ProgressGoh, Jeffrey, Pattison, David, Ngai, Stanley, Katchel, Loren, Holmes, Ingrid, Baker, Sean, Biggs, Heather, Cuscaden, Claire, Campbell, Louise, Brady, Jasmine, Lindsay, Karen, Latter, Melissa, Griffiths, Matthew, O'Mahoney, Eoin, Dhiantravan, Nattakorn, Francis, Roslyn, Rose, Stephen, Soderholm, Amelia, Baronet, Meghan, Crumbaker, Megan, Kryza, Thomas, Shakti, Stelle, Naidoo, Sheruna, Puttick, Simon, Horsfall, Aimee, Barkhausen, Christoph, Kuan, Kevin, Santoro, Paola, Skingley, Lesley ... Hansen, Aaron (2025). Phase Ib/IIa dose escalation and expansion study of 212Pb-ADVC001 in metastatic castration-resistant prostate cancer (mCRPC): TheraPb-Phase I/II Trial in Progress. HOBOKEN: WILEY. |
|
2025 Conference Publication Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumoursBurge, Matthew E., Wyld, David, Pattison, David A., Bahamad, Sandra, Hayes, Sarah J., Kuszewski, Julia A., Chantrill, Lorraine A., Price, Timothy Jay, Wong, Hui-Li, Chan, David, Grover, Piyush, Michael, Michael, Siu, Derrick, Bishop, Christine, Barker, Daniel, Goodwin, Rachel Anne, O'Callaghan, Christopher J., Loree, Jonathan M. and Mak, W. John (2025). Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours. 2025 ASCO Annual Meeting, Chicago, IL United States, 30 May - 3 June 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.tps4224 |
|
2025 Conference Publication Phase Ib/IIa dose escalation and expansion study of [ 212 Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II studyHansen, Aaron Richard, Pattison, David A., Ngai, Stanley, Karmann, Anna, Walker, Amanda J., Campbell, Louise, Brady, Jasmine, Katchel, Loren, Holmes, Ingrid, Rose, Stephen E., Baronet, Meghan C., Kryza, Thomas, Vito, Alyssa, Tieu, William, Kuan, Kevin, Griffiths, Matthew R., O’Mahoney, Eoin, Latter, Melissa, Gan, Chun Loo Loo and Wyld, David (2025). Phase Ib/IIa dose escalation and expansion study of [ 212 Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II study. 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 13-15 February 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.5_suppl.tps275 |
|
2025 Conference Publication An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)Mak, Blossom, Tran, Ben, Thomas, Hayley, Pashankar, Farzana D., Hansen, Aaron Richard, Feldman, Darren R., Huddart, Robert A, Wheater, Matthew, Dunwoodie, Elaine, Mazhar, Danish, Lawrence, Nicola Jane, Stevanovic, Amanda Gwendolyn, Birtle, Alison Jane, Oladipo, Olabode, Wyld, David, Balagtas, Jay Michael S., Stockler, Martin R., Grimison, Peter S. and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 13-15 February 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.5_suppl.tps653 |
|
2024 Conference Publication When good intentions are not enough: the development of the Equity ProcEss frameworK (EPEK) to promote equity in cancerScanlon, Brighid, Wyld, David, Durham, Jo, Toloo, Sam and Roberts, Natasha (2024). When good intentions are not enough: the development of the Equity ProcEss frameworK (EPEK) to promote equity in cancer. COSA's 51st Annual Scientific Meeting Bridging gaps, building progress, breaking down disparities, Gold Coast, QLD, Australia, 13 - 15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14116 |
|
2024 Conference Publication "Signing up for the PRoCESS [Pancreatic cancer Relatives Counselling and Education Support Service] Trial was the most important thing I did as a carer"Beesley, Vanessa L., Roset, Natalie, Turner, Jane, Yates, Patsy, Wyld, David, Eastgate, Melissa, Chan, Raymond, Collins, Louisa, Stewart, Michelle, Beebe, Hanna, Malt, Maryrose, Kelly, Caroline and Neale, Rachel (2024). "Signing up for the PRoCESS [Pancreatic cancer Relatives Counselling and Education Support Service] Trial was the most important thing I did as a carer". COSA's 51st Annual Scientific Meeting: Bridging gaps, building progress, breaking down disparities, Gold Coast, QLD, Australia, 13 - 15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14116 |
|
2024 Conference Publication Clinical risk factors associated with development of significant nerve damage during chemotherapyLi, Tiffany, Timmins, Hannah C., Horvath, Lisa G., Harrison, Michelle, Grimison, Peter, Friedlander, Michael, Marx, Gavin, Boyle, Frances, Wyld, David, Henderson, Robert, Baron-Hay, Sally, Kiernan, Matthew C., Barnes, Elizabeth H., Goldstein, David and Park, Susanna B. (2024). Clinical risk factors associated with development of significant nerve damage during chemotherapy. COSA's 51st Annual Scientific Meeting Bridging gaps, building progress, breaking down disparities, Gold Coast, QLD, Australia, 13 - 15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14117 |
|
2024 Conference Publication Patient reported measures as the optimal assessment of chemotherapy-induced peripheral neuropathyLi, Tiffany, Timmins, Hannah C., Mahfouz, Fawaz M., Trinh, Terry, Mizrahi, David, Horvath, Lisa G., Harrison, Michelle, Grimison, Peter, Friedlander, Michael, Marx, Gavin, Boyle, Frances, Wyld, David, Henderson, Robert, King, Tracy, Baron-Hay, Sally, Kiernan, Matthew C., Rutherford, Claudia, Goldstein, David and Park, Susanna B. (2024). Patient reported measures as the optimal assessment of chemotherapy-induced peripheral neuropathy. COSA's 51st Annual Scientific Meeting Bridging gaps, building progress, breaking down disparities, Gold Coast, QLD, Australia, 13 - 15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14116 |
|
2024 Conference Publication Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trialNalder, Mark, Kulasegaran, Tivya, Lundie, Ben, Woods, Rick, Eastgate, Melissa A., Wyld, David and Burge, Matthew E. (2024). Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial. 2024 ASCO Annual Meeting, Chicago, IL, United States, 31 May–4 June 2024. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2024.42.16_suppl.12121 |
|
2024 Conference Publication Identifying optimized assessment of nerve damage during chemotherapyLi, Tiffany, Timmins, Hannah C, Mahfouz, Fawaz Mayez, Mizrahi, David, Horvath, Lisa, Harrison, Michelle L., Grimison, Peter S., Friedlander, Michael, Marx, Gavin M., Boyle, Frances M., Wyld, David, Henderson, Robert, King, Tracy, Baron-Hay, Sally E., Kiernan, Matthew C, Rutherford, Claudia, Goldstein, David and Park, Susanna B (2024). Identifying optimized assessment of nerve damage during chemotherapy. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.12016 |
|
2024 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)Mak, Blossom, Tran, Ben, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Feldman, Darren R., Dunwoodie, Elaine, Lawrence, Nicola Jane, Birtle, Alison Jane, Wyld, David, Stevanovic, Amanda Gwendolyn, Balagtas, Jay Michael S., Stockler, Martin R., Davis, Ian D. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2024). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2024 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 25-27 January 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.4_suppl.tps524 |
|
2023 Conference Publication Factors that influence clinical trial participation for oncology patients in Australia: A scoping reviewYou, Kyung Ha, Lwin, Zarnie, Ahern, Elizabeth Stephanie, Roberts, Natasha Anne and Wyld, David (2023). Factors that influence clinical trial participation for oncology patients in Australia: A scoping review. 2023 ASCO Quality Care Symposium, Boston, MA United States, 27-28 October 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/op.2023.19.11_suppl.111 |
|
2023 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka Sinikovic, Ben Tran,, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R. and Grimison, Peter S. (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2023 Conference Publication An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka Sinikovic, Tran, Ben, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Annual Meeting, Chicago, IL USA, 2-6 June 2023. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps5102 |
|
2023 Conference Publication PRRT for control of hypoglycaemia and disease progression due to metastatic insulinomaPattison, D. A., Kong, G., Hofman, M. S., Akhurst, T., Ravi, Kumar A. S., Michael, M., Wyld, D., Burge, M., Chiang, C., Sachithanandan, N., Love, A. and Hicks, R. (2023). PRRT for control of hypoglycaemia and disease progression due to metastatic insulinoma. 20th Annual ENETs Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Electr Network, Mar 22-24, 2023. HOBOKEN: WILEY. |
|
2023 Conference Publication An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Tran, Ben, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J. and Grimison, Peter S. (2023). An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs). Genitourinary Cancers Symposium, Online, 16-18 February 2023. Philadelphia, PA United States: Lippincott Williams & Wilkins. |
|
2023 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Tran, Ben, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps431 |
|
2022 Conference Publication Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian settingKim, Hansoo, Kulasegaran, Tivya, Eastgate, Melissa, Wyld, David, Burge, Matthew and Nalder, Mark (2022). Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian setting. HOBOKEN: WILEY. |
